Kymera Therapeutics

KYMR

Market cap $7.31B

KYMR posts wider-than-expected Q4 loss as R&D jumps and collaboration revenues fall, but $1.6B cash haul and KT-621 progress bolster pipeline outlook.

Kymera Therapeutics, Inc. (KYMR) Q4 2025 Earnings Call Transcript

Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.97 per share versus the Zacks Consensus Estimate of a loss of $0.77. This compares to a loss of $0.88 per share a year ago.

Baker Bros. Advisors added 2,005,813 shares of Kymera Therapeutics; the estimated transaction value was $135.45 million.

Rock Springs Capital Management bought 46,497 shares of Kymera Therapeutics in the fourth quarter, with an estimated trade value of $3.14 million (based on quarterly average pricing). Meanwhile, the quarter-end position value increased by $13.17 million, reflecting share additions and price movement.

Kymera Therapeutics begins phase IIb dosing of oral KT-621 in eosinophilic asthma patients, targeting STAT6, with top-line BREADTH study data expected in late 2027.

Kymera Therapeutics, Inc. (KYMR) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript

KT-621 BROADEN2 Phase 2b trial in AD ongoing, with data expected by mid-2027 KT-621 BREADTH Phase 2b trial in asthma initiated, with data expected in late-2027 KT-579 Phase 1 HV clinical trial expected to start in 1Q26, with data expected in 2H26 Advancing at least one new development candidate towards IND for a first-in-class, oral immunology program in 2026 Well-capitalized with $1.6 billion 1 in cash and runway into 2029 Kymera to present its 2026 objectives at the J.P. Morgan 44 th Annual Healthcare Conference today at 9:00 a.m.

Kymera Therapeutics (KYMR) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

KYMR rallied 82% in a year as KT-621 delivered strong phase Ib BroADen data and earned FDA Fast Track for atopic dermatitis.